Has Jay Mason received payments from drug or device companies?

Yes. Drug and device makers reported $226,778 in general payments to Jay Mason across 46 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jay Mason did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jay Mason come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jay Mason

Cardiovascular Disease · Reno, NVNPI 1225358666

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $226,548 of the $226,778 with a category attached, or 99.9%. 12 manufacturers reported payments, led by Taiho Oncology, Inc. at 51.3% of the total. Reporting peaked in 2023 at $61,638 and has fallen 83.4% since, to $10,238 in 2025. Among cardiovascular disease clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$226,778in general payments, 2019–2025

Across 46 payments — averaging $4929.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Taiho Oncology, Inc.$116K
Almirall LLC$24K
UCB SA$21K
Daiichi Sankyo Inc.$15K
Immunomedics, Inc.$14K
Alkermes, Inc.$12K
plus $25K from 6 others

$30,687in research payments, 2019–2025

Across 10 payments — averaging $3068.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Neurocrine Biosciences, Inc.$25K
Novartis$6K

What the payments were for

Consulting fees$226,548100%
Speaking & faculty fees$2300%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Taiho Oncology, Inc.	9	$116,315
Almirall LLC	6	$24,429
UCB SA	1	$20,792
Daiichi Sankyo Inc.	11	$14,709
Immunomedics, Inc.	2	$14,168
Alkermes, Inc.	2	$11,538
Sentynl Therapeutics, Inc.	4	$7,675
Evoke Pharma, Inc.	1	$7,638
Harmony Biosciences LLC	6	$6,736
Emergent Biosolutions Inc.	2	$2,174
Gilead	1	$375
Shionogi Inc	1	$230

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Keppra$20,792
Trodelvy$14,168
VANFLYTa$3,900
Acam2000$2,174
Wakix$917
Fetroja$230

How this compares

$226,778 in reported general payments places this provider in the 95th percentile of 165 cardiovascular disease providers in Nevada.

See all cardiovascular disease providers in Nevada →

Other cardiovascular disease in Reno

See the full list for Nevada →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →